Overview

The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)

Status:
Withdrawn
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to obtain a preliminary pharmacokinetic profile of MK-7145 2 mg immediate release (IR) following single-dose administration in male participants with moderate renal insufficiency. In addition, the study will evaluate the pharmacodynamic effect of a single dose of MK-7145 2 mg IR on 24-hour net natriuresis in male participants with moderate renal insufficiency.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.